Abstract:Transcription factors (TFs) specifically bind to DNA, recruit cofactor proteins and modulate target gene expression, rendering them essential roles in the regulation of numerous biological processes. Meanwhile, mutated or dysregulated TFs are involved in a variety of human diseases. As multiple signaling pathways ultimately converge at TFs, targeting these TFs directly may prove to be more specific and cause fewer side effects, than targeting the upfront conventional targets in these pathways. All these features together endue TFs with great potential and high selectivity as therapeutic drug targets. However, TFs have been historically considered "undruggable", mainly due to their lack of structural information, especially about the appropriate ligand-binding sites and protein-protein interactions, leading to relatively limited choices in the TF-targeting drug design. In this review, we summarize the recent progress of TF-targeting drugs and highlight certain strategies used for targeting TFs, with a number of representative drugs that have been approved or in the clinical trials as examples. Various approaches in targeting TFs directly or indirectly have been developed. Common direct strategies include aiming at defined binding pockets, proteolysis-targeting chimaera (PROTAC), and mutant protein reactivation. In contrast, the indirect ones comprise inhibition of protein-protein interactions between TF and other proteins, blockade of TF expression, targeting the post-translational modifications, and targeting the TF-DNA interactions. With more comprehensive structural information about TFs revealed by the powerful cryo-electron microscopy technology and predicted by machine-learning algorithms, plus more efficient compound screening platforms and a deeper understanding of TF-disease relationships, the development of TF-targeting drugs will certainly be accelerated in the near future.

Drugging the Undruggable: Targeting the N-Terminal Domain of Nuclear Hormone Receptors

Thinking Outside the Box: Alternative Binding Sites in the Ligand Binding Domain of Nuclear Receptors

Advances in RNA therapeutics for modulation of 'undruggable' targets

Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states

Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials

Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer

Current Strategies and Progress for Targeting the “undruggable” Transcription Factors

Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective

A Magic Drug Target: Androgen Receptor

Nuclear‐targeting Peptides for Cancer Therapy

Peptide therapeutics: Targeting the undruggable space

Advances in targeting ‘undruggable’ transcription factors with small molecules

The Nuclear Receptor Field: A Historical Overview and Future Challenges

Nuclear Mechanisms Involved in Endocrine Resistance

Drugging Membrane Protein Interactions

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

A Combined Computational and Experimental Approach to Studying Tropomyosin Kinase Receptor B Binders for Potential Treatment of Neurodegenerative Diseases

Androgen receptor modulators: a review of recent patents and reports (2012-2018)

The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics.

ROR Nuclear Receptors: Structures, Related Diseases, and Drug Discovery